163 followers
RT @TAMedOncol: 📄 The SUNLAND phase II trial evaluated sunitinib + lanreotide vs placebo + lanreotide for advanced midgut NETs. Recruitment…
RT @TAMedOncol: 📄 The SUNLAND phase II trial evaluated sunitinib + lanreotide vs placebo + lanreotide for advanced midgut NETs. Recruitment…
📄 The SUNLAND phase II trial evaluated sunitinib + lanreotide vs placebo + lanreotide for advanced midgut NETs. Recruitment challenges limited conclusions, but trends favored sunitinib for QoL measures. 🔗 https://t.co/KENl2ony0l Thanks @louis_demestie…